Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 45. More products

(ignored: HYDROCHLOROTHIAZIDE)

Lisinopril was listed in the December 27, 2023 extract; the same DIN 02525186 is listed as Lisinopril (Type Z) in the current extract (Aug 26, 2026). This is not an absent DIN. Source: odb-formulary-ed43-extract-2023-12-27.xml; odb-formulary-ed43-extract-2026-08-26.xml.

Lisinopril (type z) (lisinopril) and other lisinopril products

LISINOPRIL

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C09AA) — coverage varies; not interchangeable

  • Benazepril (Lotensin): general benefit, Not a benefit
  • Captopril (Noyada): general benefit, Limited Use 707, 723, Not a benefit
  • Cilazapril (Inhibace): general benefit, Not a benefit
  • Enalapril (Vasotec): general benefit, Not a benefit
  • Fosinopril (Monopril): general benefit, Not a benefit
  • Perindopril erbumine (Coversyl): general benefit

3 more in the class list below

Lisinopril (Type Z) · DIN 02525186 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lisinopril (Type Z) · DIN 02525186 Manufacturer: Sanis Health Inc.; listing date 2022-10-31 Daily cost (source): $0.1347 Health Canada: Marketed since 2025-03-17 · brand LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 5 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Lisinopril (Type Z): Formulary list price $0.1347/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1347 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101418 · Verify on the e-Formulary ↗ (DIN 02525186)

Source record
DIN 02525186: Lisinopril (Type Z) Raw flags: chronicUseMed=Y, sec3=Y Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id SAI Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1347; ministry $0.1347 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02525186 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101418
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347 Auro-Lisinopril · DIN 02394472 · $0.1347 Co Lisinopril · DIN 02271443 · $0.1347 Jamp-Lisinopril · DIN 02361531 · $0.1347 Lisinopril · DIN 02386232 · $0.1347 Lisinopril Tablets · DIN 02554488 · $0.1347 Ran-Lisinopril · DIN 02294230 · $0.1347 Sandoz Lisinopril · DIN 02289199 · $0.1347 Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347 Zestril · DIN 02049333 · $0.1347
Shortage status: resolved shortage (ended 2025-03-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02525186
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Lisinopril (Type Z) · DIN 02285118 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Lisinopril (Type Z) · DIN 02285118 Manufacturer: Teva Canada Limited; listing date 2007-12-19 Daily cost (source): $0.1347 Health Canada: Marketed since 2010-12-09 · brand TEVA-LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 5 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Lisinopril (Type Z): Formulary list price $0.1347/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1347 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77062 · Verify on the e-Formulary ↗ (DIN 02285118)

Source record
DIN 02285118: Teva-Lisinopril (Type Z) Raw flags: chronicUseMed=Y, sec3=Y Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id TEV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1347; ministry $0.1347 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02285118 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77062
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347 Auro-Lisinopril · DIN 02394472 · $0.1347 Co Lisinopril · DIN 02271443 · $0.1347 Jamp-Lisinopril · DIN 02361531 · $0.1347 Lisinopril · DIN 02386232 · $0.1347 Lisinopril (Type Z) · DIN 02525186 · $0.1347 Lisinopril Tablets · DIN 02554488 · $0.1347 Ran-Lisinopril · DIN 02294230 · $0.1347 Sandoz Lisinopril · DIN 02289199 · $0.1347 Zestril · DIN 02049333 · $0.1347
Shortage status: resolved shortage (ended 2025-11-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285118
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lisinopril (Type Z) · DIN 02525194 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lisinopril (Type Z) · DIN 02525194 Manufacturer: Sanis Health Inc.; listing date 2022-10-31 Daily cost (source): $0.1619 Health Canada: Marketed since 2025-03-17 · brand LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 10 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Lisinopril (Type Z): Formulary list price $0.1619/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1619 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101419 · Verify on the e-Formulary ↗ (DIN 02525194)

Source record
DIN 02525194: Lisinopril (Type Z) Raw flags: chronicUseMed=Y, sec3=Y Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id SAI Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1619; ministry $0.1619 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02525194 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101419
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619 Auro-Lisinopril · DIN 02394480 · $0.1619 Co Lisinopril · DIN 02271451 · $0.1619 Jamp-Lisinopril · DIN 02361558 · $0.1619 Lisinopril · DIN 02386240 · $0.1619 Lisinopril Tablets · DIN 02554496 · $0.1619 Ran-Lisinopril · DIN 02294249 · $0.1619 Sandoz Lisinopril · DIN 02289202 · $0.1619 Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619 Zestril · DIN 02049376 · $0.1619
Shortage status: resolved shortage (ended 2025-03-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02525194
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Lisinopril (Type Z) · DIN 02285126 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Lisinopril (Type Z) · DIN 02285126 Manufacturer: Teva Canada Limited; listing date 2007-12-19 Daily cost (source): $0.1619 Health Canada: Marketed since 2010-12-09 · brand TEVA-LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 10 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Lisinopril (Type Z): Formulary list price $0.1619/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1619 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77063 · Verify on the e-Formulary ↗ (DIN 02285126)

Source record
DIN 02285126: Teva-Lisinopril (Type Z) Raw flags: chronicUseMed=Y, sec3=Y Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id TEV Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1619; ministry $0.1619 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02285126 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77063
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619 Auro-Lisinopril · DIN 02394480 · $0.1619 Co Lisinopril · DIN 02271451 · $0.1619 Jamp-Lisinopril · DIN 02361558 · $0.1619 Lisinopril · DIN 02386240 · $0.1619 Lisinopril (Type Z) · DIN 02525194 · $0.1619 Lisinopril Tablets · DIN 02554496 · $0.1619 Ran-Lisinopril · DIN 02294249 · $0.1619 Sandoz Lisinopril · DIN 02289202 · $0.1619 Zestril · DIN 02049376 · $0.1619
Shortage status: resolved shortage (ended 2025-08-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285126
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lisinopril (Type Z) · DIN 02525208 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lisinopril (Type Z) · DIN 02525208 Manufacturer: Sanis Health Inc.; listing date 2022-10-31 Daily cost (source): $0.1945 Health Canada: Marketed since 2025-03-17 · brand LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 20 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Lisinopril (Type Z): Formulary list price $0.1945/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1945 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101420 · Verify on the e-Formulary ↗ (DIN 02525208)

Source record
DIN 02525208: Lisinopril (Type Z) Raw flags: chronicUseMed=Y, sec3=Y Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id SAI Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1945; ministry $0.1945 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02525208 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101420
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945 Auro-Lisinopril · DIN 02394499 · $0.1945 Co Lisinopril · DIN 02271478 · $0.1945 Jamp-Lisinopril · DIN 02361566 · $0.1945 Lisinopril · DIN 02386259 · $0.1945 Lisinopril Tablets · DIN 02554518 · $0.1945 Ran-Lisinopril · DIN 02294257 · $0.1945 Sandoz Lisinopril · DIN 02289229 · $0.1945 Teva-Lisinopril (Type Z) · DIN 02285134 · $0.1945 Zestril · DIN 02049384 · $0.1945
Shortage status: resolved shortage (ended 2025-03-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02525208
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Lisinopril (Type Z) · DIN 02285134 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Lisinopril (Type Z) · DIN 02285134 Manufacturer: Teva Canada Limited; listing date 2007-12-19 Daily cost (source): $0.1945 Health Canada: Marketed since 2010-12-09 · brand TEVA-LISINOPRIL (TYPE Z) · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 20 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Lisinopril (Type Z): Formulary list price $0.1945/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1945 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77064 · Verify on the e-Formulary ↗ (DIN 02285134)

Source record
DIN 02285134: Teva-Lisinopril (Type Z) Raw flags: chronicUseMed=Y, sec3=Y Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id TEV Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1945; ministry $0.1945 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02285134 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77064
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945 Auro-Lisinopril · DIN 02394499 · $0.1945 Co Lisinopril · DIN 02271478 · $0.1945 Jamp-Lisinopril · DIN 02361566 · $0.1945 Lisinopril · DIN 02386259 · $0.1945 Lisinopril (Type Z) · DIN 02525208 · $0.1945 Lisinopril Tablets · DIN 02554518 · $0.1945 Ran-Lisinopril · DIN 02294257 · $0.1945 Sandoz Lisinopril · DIN 02289229 · $0.1945 Zestril · DIN 02049384 · $0.1945
Shortage status: resolved shortage (ended 2025-05-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285134
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Lisinopril · DIN 02394472 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Lisinopril · DIN 02394472 Manufacturer: Auro Pharma Inc.; listing date 2013-04-30 Daily cost (source): $0.1347 Health Canada: Marketed since 2013-02-12 · brand AURO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 5 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Lisinopril: Formulary list price $0.1347/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1347 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87963 · Verify on the e-Formulary ↗ (DIN 02394472)

Source record
DIN 02394472: Auro-Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id AUR Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1347; ministry $0.1347 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02394472 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87963
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347 Co Lisinopril · DIN 02271443 · $0.1347 Jamp-Lisinopril · DIN 02361531 · $0.1347 Lisinopril · DIN 02386232 · $0.1347 Lisinopril (Type Z) · DIN 02525186 · $0.1347 Lisinopril Tablets · DIN 02554488 · $0.1347 Ran-Lisinopril · DIN 02294230 · $0.1347 Sandoz Lisinopril · DIN 02289199 · $0.1347 Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347 Zestril · DIN 02049333 · $0.1347
Shortage status: resolved shortage (ended 2026-01-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394472
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lisinopril Tablets · DIN 02554488 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lisinopril Tablets · DIN 02554488 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2026-01-30 Daily cost (source): $0.1347 Health Canada: Marketed since 2025-12-29 · brand LISINOPRIL TABLETS · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Lisinopril Tablets: Formulary list price $0.1347/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1347 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104333 · Verify on the e-Formulary ↗ (DIN 02554488)

Source record
DIN 02554488: Lisinopril Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id SIV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1347; ministry $0.1347 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554488 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104333
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347 Auro-Lisinopril · DIN 02394472 · $0.1347 Co Lisinopril · DIN 02271443 · $0.1347 Jamp-Lisinopril · DIN 02361531 · $0.1347 Lisinopril · DIN 02386232 · $0.1347 Lisinopril (Type Z) · DIN 02525186 · $0.1347 Ran-Lisinopril · DIN 02294230 · $0.1347 Sandoz Lisinopril · DIN 02289199 · $0.1347 Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347 Zestril · DIN 02049333 · $0.1347
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554488
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zestril · DIN 02049333 · 5mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Zestril (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists ZESTRIL (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Zestril · DIN 02049333 Manufacturer: AstraZeneca; listing date 1996-10-01 Daily cost (source): $0.5770 Health Canada: Marketed since 2022-02-28 · brand ZESTRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 5 MG · company Searchlight pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1347 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17126 · Verify on the e-Formulary ↗ (DIN 02049333)

Source record
DIN 02049333: Zestril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id AZC Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.5770; ministry $0.1347 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02049333 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17126
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347 Auro-Lisinopril · DIN 02394472 · $0.1347 Co Lisinopril · DIN 02271443 · $0.1347 Jamp-Lisinopril · DIN 02361531 · $0.1347 Lisinopril · DIN 02386232 · $0.1347 Lisinopril (Type Z) · DIN 02525186 · $0.1347 Lisinopril Tablets · DIN 02554488 · $0.1347 Ran-Lisinopril · DIN 02294230 · $0.1347 Sandoz Lisinopril · DIN 02289199 · $0.1347 Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347
Shortage status: resolved shortage (ended 2026-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02049333
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Lisinopril · DIN 02394480 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Lisinopril · DIN 02394480 Manufacturer: Auro Pharma Inc.; listing date 2013-04-30 Daily cost (source): $0.1619 Health Canada: Marketed since 2013-02-12 · brand AURO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 10 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Lisinopril: Formulary list price $0.1619/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1619 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87964 · Verify on the e-Formulary ↗ (DIN 02394480)

Source record
DIN 02394480: Auro-Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id AUR Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1619; ministry $0.1619 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02394480 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87964
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619 Co Lisinopril · DIN 02271451 · $0.1619 Jamp-Lisinopril · DIN 02361558 · $0.1619 Lisinopril · DIN 02386240 · $0.1619 Lisinopril (Type Z) · DIN 02525194 · $0.1619 Lisinopril Tablets · DIN 02554496 · $0.1619 Ran-Lisinopril · DIN 02294249 · $0.1619 Sandoz Lisinopril · DIN 02289202 · $0.1619 Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619 Zestril · DIN 02049376 · $0.1619
Shortage status: resolved shortage (ended 2025-03-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394480
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lisinopril Tablets · DIN 02554496 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lisinopril Tablets · DIN 02554496 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2026-01-30 Daily cost (source): $0.1619 Health Canada: Marketed since 2025-12-29 · brand LISINOPRIL TABLETS · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Lisinopril Tablets: Formulary list price $0.1619/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1619 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104334 · Verify on the e-Formulary ↗ (DIN 02554496)

Source record
DIN 02554496: Lisinopril Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id SIV Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1619; ministry $0.1619 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554496 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104334
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619 Auro-Lisinopril · DIN 02394480 · $0.1619 Co Lisinopril · DIN 02271451 · $0.1619 Jamp-Lisinopril · DIN 02361558 · $0.1619 Lisinopril · DIN 02386240 · $0.1619 Lisinopril (Type Z) · DIN 02525194 · $0.1619 Ran-Lisinopril · DIN 02294249 · $0.1619 Sandoz Lisinopril · DIN 02289202 · $0.1619 Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619 Zestril · DIN 02049376 · $0.1619
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554496
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zestril · DIN 02049376 · 10mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Zestril (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists ZESTRIL (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Zestril · DIN 02049376 Manufacturer: AstraZeneca; listing date 1996-10-01 Daily cost (source): $0.6935 Health Canada: Marketed since 2022-02-28 · brand ZESTRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 10 MG · company Searchlight pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1619 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17215 · Verify on the e-Formulary ↗ (DIN 02049376)

Source record
DIN 02049376: Zestril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id AZC Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.6935; ministry $0.1619 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02049376 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17215
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619 Auro-Lisinopril · DIN 02394480 · $0.1619 Co Lisinopril · DIN 02271451 · $0.1619 Jamp-Lisinopril · DIN 02361558 · $0.1619 Lisinopril · DIN 02386240 · $0.1619 Lisinopril (Type Z) · DIN 02525194 · $0.1619 Lisinopril Tablets · DIN 02554496 · $0.1619 Ran-Lisinopril · DIN 02294249 · $0.1619 Sandoz Lisinopril · DIN 02289202 · $0.1619 Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619
Shortage status: resolved shortage (ended 2025-12-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02049376
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Lisinopril · DIN 02394499 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Lisinopril · DIN 02394499 Manufacturer: Auro Pharma Inc.; listing date 2013-04-30 Daily cost (source): $0.1945 Health Canada: Marketed since 2013-02-12 · brand AURO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 20 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Lisinopril: Formulary list price $0.1945/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1945 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87965 · Verify on the e-Formulary ↗ (DIN 02394499)

Source record
DIN 02394499: Auro-Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id AUR Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1945; ministry $0.1945 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02394499 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87965
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945 Co Lisinopril · DIN 02271478 · $0.1945 Jamp-Lisinopril · DIN 02361566 · $0.1945 Lisinopril · DIN 02386259 · $0.1945 Lisinopril (Type Z) · DIN 02525208 · $0.1945 Lisinopril Tablets · DIN 02554518 · $0.1945 Ran-Lisinopril · DIN 02294257 · $0.1945 Sandoz Lisinopril · DIN 02289229 · $0.1945 Teva-Lisinopril (Type Z) · DIN 02285134 · $0.1945 Zestril · DIN 02049384 · $0.1945
Shortage status: resolved shortage (ended 2026-01-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02394499
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lisinopril Tablets · DIN 02554518 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lisinopril Tablets · DIN 02554518 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2026-01-30 Daily cost (source): $0.1945 Health Canada: Marketed since 2025-12-29 · brand LISINOPRIL TABLETS · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 20 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Lisinopril Tablets: Formulary list price $0.1945/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1945 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104335 · Verify on the e-Formulary ↗ (DIN 02554518)

Source record
DIN 02554518: Lisinopril Tablets Raw flags: chronicUseMed=Y, sec3=Y Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id SIV Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1945; ministry $0.1945 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554518 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104335
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945 Auro-Lisinopril · DIN 02394499 · $0.1945 Co Lisinopril · DIN 02271478 · $0.1945 Jamp-Lisinopril · DIN 02361566 · $0.1945 Lisinopril · DIN 02386259 · $0.1945 Lisinopril (Type Z) · DIN 02525208 · $0.1945 Ran-Lisinopril · DIN 02294257 · $0.1945 Sandoz Lisinopril · DIN 02289229 · $0.1945 Teva-Lisinopril (Type Z) · DIN 02285134 · $0.1945 Zestril · DIN 02049384 · $0.1945
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554518
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Zestril · DIN 02049384 · 20mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Zestril (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
Savings card: RxHelp ONE lists ZESTRIL (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
Limit of one Prescription Drug Card Program / Patient Financial Assistance Card from any adjudicator per DIN and claim submitted. The RxHelpONE card CANNOT be combined with any other card or offer. (Terms of Use) (rxhelp.ca, Sep 10, 2026 ↗)
1 brand, same coverage
Zestril · DIN 02049384 Manufacturer: AstraZeneca; listing date 1996-10-01 Daily cost (source): $0.8330 Health Canada: Marketed since 2022-02-28 · brand ZESTRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 20 MG · company Searchlight pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.1945 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17123 · Verify on the e-Formulary ↗ (DIN 02049384)

Source record
DIN 02049384: Zestril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id AZC Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.8330; ministry $0.1945 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02049384 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17123
Interchangeable products
Apo-Lisinopril · DIN 02217511 · $0.1945 Auro-Lisinopril · DIN 02394499 · $0.1945 Co Lisinopril · DIN 02271478 · $0.1945 Jamp-Lisinopril · DIN 02361566 · $0.1945 Lisinopril · DIN 02386259 · $0.1945 Lisinopril (Type Z) · DIN 02525208 · $0.1945 Lisinopril Tablets · DIN 02554518 · $0.1945 Ran-Lisinopril · DIN 02294257 · $0.1945 Sandoz Lisinopril · DIN 02289229 · $0.1945 Teva-Lisinopril (Type Z) · DIN 02285134 · $0.1945
Shortage status: resolved shortage (ended 2024-11-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02049384
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Lisinopril · DIN 02217481 · 5mg · tablet

General benefitDormant since 2026-02-04 · checked 2026-09-02 · What does dormant mean?
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lisinopril · DIN 02217481 Manufacturer: Apotex Inc.; listing date 1997-08-28 Daily cost (source): $0.1347 Health Canada: Dormant since 2026-02-04 · brand APO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 5 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Lisinopril: Formulary list price $0.1347/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1347 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43221 · Verify on the e-Formulary ↗ (DIN 02217481)

Source record
DIN 02217481: Apo-Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id APX Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1347; ministry $0.1347 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02217481 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43221
Interchangeable products
Auro-Lisinopril · DIN 02394472 · $0.1347 Co Lisinopril · DIN 02271443 · $0.1347 Jamp-Lisinopril · DIN 02361531 · $0.1347 Lisinopril · DIN 02386232 · $0.1347 Lisinopril (Type Z) · DIN 02525186 · $0.1347 Lisinopril Tablets · DIN 02554488 · $0.1347 Ran-Lisinopril · DIN 02294230 · $0.1347 Sandoz Lisinopril · DIN 02289199 · $0.1347 Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347 Zestril · DIN 02049333 · $0.1347
Shortage status: active shortage (reported 2025-01-28, last updated 2025-01-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02217481
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-02-04 — choose a marketed DIN from the same-category list.

Jamp-Lisinopril · DIN 02361531 · 5mg · tablet

General benefitDormant since 2025-10-31 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Lisinopril · DIN 02361531 Manufacturer: Jamp Pharma Corporation; listing date 2012-01-19 Daily cost (source): $0.1347 Health Canada: Dormant since 2025-10-31 · brand JAMP-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 5 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Lisinopril: Formulary list price $0.1347/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1347 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84661 · Verify on the e-Formulary ↗ (DIN 02361531)

Source record
DIN 02361531: Jamp-Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id JPC Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1347; ministry $0.1347 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02361531 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84661
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347 Auro-Lisinopril · DIN 02394472 · $0.1347 Co Lisinopril · DIN 02271443 · $0.1347 Lisinopril · DIN 02386232 · $0.1347 Lisinopril (Type Z) · DIN 02525186 · $0.1347 Lisinopril Tablets · DIN 02554488 · $0.1347 Ran-Lisinopril · DIN 02294230 · $0.1347 Sandoz Lisinopril · DIN 02289199 · $0.1347 Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347 Zestril · DIN 02049333 · $0.1347
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361531
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-10-31 — choose a marketed DIN from the same-category list.

Lisinopril · DIN 02386232 · 5mg · tablet

General benefitDormant since 2026-07-03 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lisinopril · DIN 02386232 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-10-30 Daily cost (source): $0.1347 Health Canada: Dormant since 2026-07-03 · brand LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Lisinopril: Formulary list price $0.1347/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1347 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87181 · Verify on the e-Formulary ↗ (DIN 02386232)

Source record
DIN 02386232: Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id SIV Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1347; ministry $0.1347 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386232 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87181
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347 Auro-Lisinopril · DIN 02394472 · $0.1347 Co Lisinopril · DIN 02271443 · $0.1347 Jamp-Lisinopril · DIN 02361531 · $0.1347 Lisinopril (Type Z) · DIN 02525186 · $0.1347 Lisinopril Tablets · DIN 02554488 · $0.1347 Ran-Lisinopril · DIN 02294230 · $0.1347 Sandoz Lisinopril · DIN 02289199 · $0.1347 Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347 Zestril · DIN 02049333 · $0.1347
Shortage status: active shortage (reported 2025-03-21, estimated to end 2026-12-01, last updated 2025-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02386232
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-03 — choose a marketed DIN from the same-category list.

Ran-Lisinopril · DIN 02294230 · 5mg · tablet

General benefitDormant since 2024-05-31 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Lisinopril · DIN 02294230 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-12-19 Daily cost (source): $0.1347 Health Canada: Dormant since 2024-05-31 · brand TARO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 5 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Lisinopril: Formulary list price $0.1347/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1347 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77958 · Verify on the e-Formulary ↗ (DIN 02294230)

Source record
DIN 02294230: Ran-Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800150; group id 333; item number 0748; lccId None; manufacturer id RAN Source form: Tab; strength: 5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1347; ministry $0.1347 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02294230 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77958
Interchangeable products
Apo-Lisinopril · DIN 02217481 · $0.1347 Auro-Lisinopril · DIN 02394472 · $0.1347 Co Lisinopril · DIN 02271443 · $0.1347 Jamp-Lisinopril · DIN 02361531 · $0.1347 Lisinopril · DIN 02386232 · $0.1347 Lisinopril (Type Z) · DIN 02525186 · $0.1347 Lisinopril Tablets · DIN 02554488 · $0.1347 Sandoz Lisinopril · DIN 02289199 · $0.1347 Teva-Lisinopril (Type Z) · DIN 02285118 · $0.1347 Zestril · DIN 02049333 · $0.1347
Shortage status: resolved shortage (ended 2021-11-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02294230
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-05-31 — choose a marketed DIN from the same-category list.

Apo-Lisinopril · DIN 02217503 · 10mg · tablet

General benefitDormant since 2024-12-09 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lisinopril · DIN 02217503 Manufacturer: Apotex Inc.; listing date 2001-06-07 Daily cost (source): $0.1619 Health Canada: Dormant since 2024-12-09 · brand APO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 10 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Lisinopril: Formulary list price $0.1619/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1619 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43222 · Verify on the e-Formulary ↗ (DIN 02217503)

Source record
DIN 02217503: Apo-Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id APX Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1619; ministry $0.1619 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02217503 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43222
Interchangeable products
Auro-Lisinopril · DIN 02394480 · $0.1619 Co Lisinopril · DIN 02271451 · $0.1619 Jamp-Lisinopril · DIN 02361558 · $0.1619 Lisinopril · DIN 02386240 · $0.1619 Lisinopril (Type Z) · DIN 02525194 · $0.1619 Lisinopril Tablets · DIN 02554496 · $0.1619 Ran-Lisinopril · DIN 02294249 · $0.1619 Sandoz Lisinopril · DIN 02289202 · $0.1619 Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619 Zestril · DIN 02049376 · $0.1619
Shortage status: active shortage (reported 2023-12-12, last updated 2024-04-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02217503
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-12-09 — choose a marketed DIN from the same-category list.

Jamp-Lisinopril · DIN 02361558 · 10mg · tablet

General benefitDormant since 2025-10-31 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Lisinopril · DIN 02361558 Manufacturer: Jamp Pharma Corporation; listing date 2012-01-19 Daily cost (source): $0.1619 Health Canada: Dormant since 2025-10-31 · brand JAMP-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 10 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Lisinopril: Formulary list price $0.1619/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1619 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84662 · Verify on the e-Formulary ↗ (DIN 02361558)

Source record
DIN 02361558: Jamp-Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id JPC Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1619; ministry $0.1619 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02361558 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84662
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619 Auro-Lisinopril · DIN 02394480 · $0.1619 Co Lisinopril · DIN 02271451 · $0.1619 Lisinopril · DIN 02386240 · $0.1619 Lisinopril (Type Z) · DIN 02525194 · $0.1619 Lisinopril Tablets · DIN 02554496 · $0.1619 Ran-Lisinopril · DIN 02294249 · $0.1619 Sandoz Lisinopril · DIN 02289202 · $0.1619 Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619 Zestril · DIN 02049376 · $0.1619
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02361558
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-10-31 — choose a marketed DIN from the same-category list.

Lisinopril · DIN 02386240 · 10mg · tablet

General benefitDormant since 2026-07-03 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lisinopril · DIN 02386240 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-10-30 Daily cost (source): $0.1619 Health Canada: Dormant since 2026-07-03 · brand LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 10 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Lisinopril: Formulary list price $0.1619/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1619 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87182 · Verify on the e-Formulary ↗ (DIN 02386240)

Source record
DIN 02386240: Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id SIV Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1619; ministry $0.1619 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386240 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87182
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619 Auro-Lisinopril · DIN 02394480 · $0.1619 Co Lisinopril · DIN 02271451 · $0.1619 Jamp-Lisinopril · DIN 02361558 · $0.1619 Lisinopril (Type Z) · DIN 02525194 · $0.1619 Lisinopril Tablets · DIN 02554496 · $0.1619 Ran-Lisinopril · DIN 02294249 · $0.1619 Sandoz Lisinopril · DIN 02289202 · $0.1619 Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619 Zestril · DIN 02049376 · $0.1619
Shortage status: active shortage (reported 2024-08-10, estimated to end 2026-12-01, last updated 2025-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02386240
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2026-07-03 — choose a marketed DIN from the same-category list.

Ran-Lisinopril · DIN 02294249 · 10mg · tablet

General benefitDormant since 2024-05-31 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Lisinopril · DIN 02294249 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2007-12-19 Daily cost (source): $0.1619 Health Canada: Dormant since 2024-05-31 · brand TARO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL (LISINOPRIL DIHYDRATE) 10 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Lisinopril: Formulary list price $0.1619/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1619 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77959 · Verify on the e-Formulary ↗ (DIN 02294249)

Source record
DIN 02294249: Ran-Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800151; group id 333; item number 0749; lccId None; manufacturer id RAN Source form: Tab; strength: 10mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1619; ministry $0.1619 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02294249 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77959
Interchangeable products
Apo-Lisinopril · DIN 02217503 · $0.1619 Auro-Lisinopril · DIN 02394480 · $0.1619 Co Lisinopril · DIN 02271451 · $0.1619 Jamp-Lisinopril · DIN 02361558 · $0.1619 Lisinopril · DIN 02386240 · $0.1619 Lisinopril (Type Z) · DIN 02525194 · $0.1619 Lisinopril Tablets · DIN 02554496 · $0.1619 Sandoz Lisinopril · DIN 02289202 · $0.1619 Teva-Lisinopril (Type Z) · DIN 02285126 · $0.1619 Zestril · DIN 02049376 · $0.1619
Shortage status: resolved shortage (ended 2021-03-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02294249
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-05-31 — choose a marketed DIN from the same-category list.

Apo-Lisinopril · DIN 02217511 · 20mg · tablet

General benefitDormant since 2025-04-07 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lisinopril · DIN 02217511 Manufacturer: Apotex Inc.; listing date 2001-06-07 Daily cost (source): $0.1945 Health Canada: Dormant since 2025-04-07 · brand APO-LISINOPRIL · ATC C09AA03 LISINOPRIL · form Tablet · route Oral · ingredients LISINOPRIL 20 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Lisinopril: Formulary list price $0.1945/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1945 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43223 · Verify on the e-Formulary ↗ (DIN 02217511)

Source record
DIN 02217511: Apo-Lisinopril Raw flags: chronicUseMed=Y, sec3=Y Item: 240800152; group id 333; item number 0750; lccId None; manufacturer id APX Source form: Tab; strength: 20mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1945; ministry $0.1945 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02217511 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43223
Interchangeable products
Auro-Lisinopril · DIN 02394499 · $0.1945 Co Lisinopril · DIN 02271478 · $0.1945 Jamp-Lisinopril · DIN 02361566 · $0.1945 Lisinopril · DIN 02386259 · $0.1945 Lisinopril (Type Z) · DIN 02525208 · $0.1945 Lisinopril Tablets · DIN 02554518 · $0.1945 Ran-Lisinopril · DIN 02294257 · $0.1945 Sandoz Lisinopril · DIN 02289229 · $0.1945 Teva-Lisinopril (Type Z) · DIN 02285134 · $0.1945 Zestril · DIN 02049384 · $0.1945
Shortage status: active shortage (reported 2024-04-02, last updated 2024-04-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02217511
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-04-07 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab

PERINDOPRIL ERBUMINE

· 45 products · General benefit · strengths: 2mg, 4mg, 8mg · Tab

QUINAPRIL

· 12 products · Listed, not a benefit (4), General benefit (8) · strengths: 5mg, 10mg, 20mg, 40mg · Tab

RAMIPRIL

· 67 products · General benefit (57), Listed, not a benefit (4), Off-Formulary Interchangeable, not an ODB benefit (6) · strengths: 1.25mg, 2.5mg, 5mg, 10mg, 15mg · Cap

TRANDOLAPRIL

· 26 products · Off-Formulary Interchangeable, not an ODB benefit (5), General benefit (21) · strengths: 0.5mg, 1mg, 2mg, 4mg · Cap

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS ZESTRIL (lisinopril) is indicated in adults for: • Hypertension: in the treatment of essential hypertension and in renovascular hypertension, alone or in combination with thiazide diuretics. A great majority of patients (>80%) with severe hypertension required combination therapy. • Heart Failure: in the management of symptomatic congestive heart failure as adjunctive treatment with diuretics, and where appropriate, digitalis. Treatment with ZESTRIL should be initiated under close medical supervision, usually in a hospital. High doses of ZESTRIL reduce the risk of the combined outcomes of mortality and hospitalization (see 4 DOSAGE AND ADMINISTRATION and 10 CLINICAL PHARMACOLOGY). • Acute Myocardial Infarction: in the treatment of hemodynamically stable patients as early as within 24 hours following acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, ASA and beta blocker(s). Therapy with ZESTRIL should be reassessed after 6 weeks. If there is no evidence of symptomatic or asymptomatic left ventricular dysfunction, treatment with ZESTRIL can be sto… https://pdf.hres.ca/dpd_pm/00073496.PDF PM date: not printed or not captured Source product: ZESTRIL; DIN 02049333; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Lisinopril · DIN 02217481 Shortage status: active shortage (reported 2025-01-28, last updated 2025-01-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02217481

Check this DIN again

Lisinopril · DIN 02386232 Shortage status: active shortage (reported 2025-03-21, estimated to end 2026-12-01, last updated 2025-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02386232

Check this DIN again

Apo-Lisinopril · DIN 02217503 Shortage status: active shortage (reported 2023-12-12, last updated 2024-04-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02217503

Check this DIN again

Lisinopril · DIN 02386240 Shortage status: active shortage (reported 2024-08-10, estimated to end 2026-12-01, last updated 2025-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02386240

Check this DIN again

Apo-Lisinopril · DIN 02217511 Shortage status: active shortage (reported 2024-04-02, last updated 2024-04-05) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02217511

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)